Research programme: neuro-inflammatory therapeutics - Xalud Therapeutics
Latest Information Update: 28 May 2022
At a glance
- Originator Xalud Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Interleukin 10 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; CNS disorders; Rheumatoid arthritis
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in CNS-disorders in USA (Parenteral)
- 28 Apr 2018 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA (Parenteral, Injection)
- 28 Apr 2018 No recent reports of development identified for research development in Rheumatoid-arthritis in USA (Parenteral, Injection)